• Latest Posts

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

FDA clears insulin pen medical device

TrialSpark acquires immunodermatology portfolio and creates Libertas Bio

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

Interview 14 Nov 2022

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

Prurigo nodularis treatment recommended for EU approval  


Sanofi and GSK Covid-19 booster vaccine approved by European Commission

More News! 4 Nov 2022

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

Late-breaking data shows significant remission in children with EoE

TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies

Treatment for adults with chronic skin condition approved by FDA

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies